Brief presentation of new Biotech VC Fund promoted by CRB Inverbio

1. Private and Confidential
CRB Bio II: A New Investment
Opportunity in Biotech
November, 2010

2. A Unique Spanish Biotech Initiative
A new Venture Capital Fund specialized in early stage investment in the
biotechnology sector with a target fund size of €60 million.
 The Fund will be managed by a new Venture Capital Firm (CRB Inverbío) created
by the founding partners of Cross Road Biotech, a Spanish venture capital
company with wide experience and track record in biotech project management.
 Cross Road Biotech currently has a diversified portfolio of eleven companies in the
biomedicine sector at different stages of development.
 Cross Road Biotech has achieved a unique know how in the Spanish venture
capital market specialized in biotechnology and its portfolio will generate net
returns several times higher than the investment.
Cross Road Biotech SCR - Confidential InformationP. 2

3.  The new Fund is anchored on six differential competitive advantages to generate
high financial returns
3
A Unique Spanish Biotech Initiative
Experience and track
record in continuous
value creation in the
biotech industry
Deep scientific
understanding and
extensive network of
contacts
Experienced
Management Team with
high credibility, led by
Enrique Castellón
Proven capacity to
access non dilutable
funds as a way of
leveraging investments
Hands on involvement
in the management and
divestment strategy,
adding value from the
first moment
Leadership position in a
growing sector in Spain
allowing CRB to attract
and generate proprietary
operations
Cross Road Biotech SCR - Confidential Information

4. P. 4
Enrique Castellón – CEO & Chairman
PhD in Medicine, Economist. Former Secretary of State for Health and Consumers in
the Health and Consumer Ministry. Chairman of the Spanish Medicines' Agency.
Creation of national oncological research centers (CNIO) and cardiovascular disease
centers (CNIC). Deputy minister for Health and Social Services in the region of
Madrid . General Manager of the health service of Galicia
Pablo Cabello – Technical and Scientific Director
Molecular Biologist. Professional experience in the Instituto de Biología Celular.
Histopathology services in the Fundación Jiménez Diaz Hospital.
20 years in the Molecular Genetics laboratory of the Hospital Ramón y Cajal.
Executive Team -
Founding partners
Manuel Castellón – Managing Director.
Lawyer and Economist. Master in Legal Counselling. 25 years of experience as
corporate lawyer . Director and certified company counsel in various companies
including Antena 3 Radio and Grupo Prisa. Founder of Castellón Abogados.
Founding Team of CRB Inverbío
Cross Road Biotech SCR - Confidential Information
Angel Santos – Director of Business Development
Engineer. Has developed his career in Spain, the UK and the US in companies such as
Johnson's Wax and Lilly, in which he has held different leadership positions in
general management, strategic and corporate development, M&A, business
development and innovation management.

5. Cross Road Biotech: a history of success
0
5
10
15
20
25
30
35
2002 2003 2004 2005 2006 2007 2008 2009 2010
Evolution of assets under management
CRB Capital Increase
11 Companies
+€32M invested
82 job creation
38 patents
P. 5 Cross Road Biotech SCR - Confidential Information
CRB has demonstrated capacity identifying and developing
biotechnology companies in the human health sector, creating value for
shareholders

6. Current portfolio. Companies
P. 6 - Cross Road Biotech SCR - Confidential Information
LACTEST
• Test for lactose intolerance which is able to measure the level of intolerance of the patient
• Overcomes the deficiencies of current systems. Simple production, rapid evaluation of
results.
TCD PHARMA
• Platform with therapeutical compounds and prognostic solutions for treating different
types of cancer, using an innovative and technically viable approach to the diseases.
• The approach is based on new therapeutical targets such as Choline Kinase and the
development of potential inhibitors.
GREEN MOLECULAR
• A technology platform of naturally occuring polyphenols with multiple indications in huge
prevalence areas.
• Anti-tumoral and anti-metastasic in high incidence cancer types: colorrectal and malignant
melanoma. Also anti-inflamatory, anti-aging and dermo protection.

7. Current portfolio. Companies
P. 7 - Cross Road Biotech SCR - Confidential Information
EMBRYOMICS
• The aim is to improve and simplify the pre-implantational analysis that determine the
viability and absence of some illnesses in human reproduction treatments.
• This advance will be a step forward compared to the previous methods of diagnostic,
avoiding the use of invasive procedures.
OWL GENOMICS
• A biotechnology company that develops new diagnostic systems and therapeutic targets
based on metabolomics.
• The company has identified Steatosis and NASH biomarkers that compound a
metabolomic signature with diagnostic value that is being first introduced in the Spanish
Hospital market.
BIOCROSS
• Non-invasive serum based diagnostic test for Alzheimer´s disease which overcomes the
unreliability of current clinical evaluations.
• The test is designed to be used to discriminate Alzheimer´s from other types of dementia.

8. Current portfolio. Companies
P. 8 - Cross Road Biotech SCR - Confidential Information
NLIFE / DENDRICO
• nLife Therapeutics is a discovery-stage biopharmaceutical company using the development
and potential commercialization of proprietary therapeutics based on RNA interferences
and DNA vaccines for the treatment of human diseases.
• The nanotherapeutics company is focused on major depression disorders, obesity and a
new generation of vaccines for influenza.
NEOCODEX
• NeoCodex is working with leading global pharmaceutical, government and academic
institutions in the design and implementation of new biomarker studies. The company
owns patents on genetic markers related to cardiovascular risk, osteoporosis and
reproductive abnormalities.
• The company is bringing together the best of biomaterials and innovative genomic analysis
methods to the world of genomic discovery, diagnostics and drug development.
GENOMADRID
• Diagnostic test for detecting the proviral charge of HIV to allow a better monitoring of the
disease.
• The kit will enable the forecasting of the evolution and to determine the continuity
termination or suspension of the treatment for HIV patients.

9. Current portfolio. Equity Position
Services Products DivestmentSe
LIVER DISEASES AND
METABOLOMICS
41,7%
(2006)
(2009)
(2013)
LACTOSE
INTOLERANCE
51,4%
(-)
(2009)
(2010)
FARMACOGENOMICS
4,5%
(2006)
(2007)
(2010)
ALZHEIMER
DIAGNOSTICS
90,8%
(-)
(-)
(2011)
siRNA THERAPEUTICAL APPLICATIONS
NANOTECHNOLOGY
DRUG DELIVERY
ONCOLOGY
63,4%
(-)
(2011)
(2013)
VIH DIAGNOSTICS
99,7%
(-)
(2010)
(2010)
ONCOLOGY
74,9%
(-)
(-)
(2013)
PREIMPLANTATIONAL
DIAGNOSIS
CRB 5%
OWL 30%
(2010)
(2011)
(2014)
100%
(-)
(-)
(2010)
50%
(-)
(-)
(2014)
P. 9 Cross Road Biotech SCR - Confidential Information

10. The Management Team of CRB promotes the creation of a
new Venture Capital Firm named CRB Inverbío
 The partners and founders of CRB have achieved a unique know how in the
Spanish venture capital market specialized in biotechnology.
 The constitution of a new fund promoted by the Venture Capital Firm will give
continuity to CRB´s entrepreneurial initiative.
 There are many new projects with great potential that can be consider into the
new structure of CRB Inverbío.
 CRB Inverbío fills in a market segment that does not count with other parties,
which represents an opportunity for accessing proprietary investments and thus, a
competitive advantage.
 There is an increasing interest from the regional and local governments and
institutions in promoting specialized investment vehicles in biotechnology.
 CRB Inverbío is well positioned to be the reference partner to this initiatives.
P. 10 Cross Road Biotech SCR - Confidential Information

11. Outline of the Transition
Managing
Team
CRB SCR
Managing
Team
Current
CRB
portfolio
BIO II
Fund
Other
Funds
Venture Capital Firm
P. 11 Cross Road Biotech SCR - Confidential Information
New
Projects

12. Vision and Mision of the new BIO II Fund
• Vision
The most profitable Spanish fund specialized in life sciences at initial
stages, developing business projects based on new scientific solutions
that cover unmet medical and or technological needs.
• Mision
 To select the best business projects based on advanced science and
technology and with great opportunities for value creation.
 To guarantee the best development, financing and strategic
management until the clinic or industrial proof of concept that maximizes
the value equation.
 Divest with added value that will assure big returns to the investors.
P. 12 Cross Road Biotech SCR - Confidential Information

13. Strategy and magnitudes of the new Bio II Fund
• Name: CRB Bio II Fund
• Size of Fund: €60 M first close November 2010
• Duration: 8 years (+2)
• Investment period: 3 years (+1)
• Minimum investment: Depending upon project needs
• Maximum investment: up to 15% of the fund
• Follow-on Investment paced in multiple rounds upon
milestone achievement
• Number of investments: 10-12
• Investment outside Spain: max 10%
• Investment in biomedicine: up to 80%
• Investment in med tech: up to 10%
• Investment in other life sciences: up to 20%
13 Cross Road Biotech SCR - Confidential Information

14. Investment Strategy will look for a balanced portfolio
 Technology and field of operation
• The investment strategy mandates the majority of the Fund to be invested in
the biomedicine field as this is the area where CRB has developed its expertise
and know how.
• However the new Fund will extend its reach and consider investments in
closely related fields of operations and technologies including:
– Agriculture and Animal health
– Medical Devices and medical technologies
– Bioinformatics
• There are many opportunities in these areas, in general require shorter
development and maturation time and are less capital intensive and still have
good exit options, therefore representing a good option to balance the
portfolio.
• The new Fund will not invest in industrial biotech.
14 Cross Road Biotech SCR - Confidential Information

15. Timing for the incorporation of the Fund
15
2Q 3Q 4Q 1Q 2Q
2010
Venture Capital Investment Firm
incorporation (CRB Inverbío)
CRB Bio II Fund incorporation
Fund raising
1st Fund closing
2nd Fund closing
Ordinary operations
30/XII
2011
Cross Road Biotech SCR - Confidential Information
30/IV

16. Almagro 1, 1º derecha
28010 Madrid, Spain
Tel.: +00 34 91 446 7897
Email: info@crbinverbio.com
Web: www.crossroadbiotech.com